The results of a new study suggest that one in five Covid-19 patients with diabetes as a comorbidity is likely to die after infection.
The French CORONADO study, published in the government journal Clinical Trials, had started during the first wave of the pandemic in early 2020.
The preliminary investigation of the study had shown that 10.6 percent of patients with type 2 diabetes and Covid-19 and 5.6 percent of patients with type 1 diabetes and Covid-19 died within a week of hospitalization.
The researchers carried out further research published in the journal Diabetologia that included 2,796 Covid-19 patients with diabetes hospitalized between March 10 and April 10, 2020 in 68 facilities across France and for 28 days long followed.
The researchers observed that the primary outcome was tracheal intubation and / or death.
“We have put together all the relevant medical information: anamnesis, usual treatment, clinical and biological presentation and hospital prognosis,” says Dr. med. Matthieu Wargny, L’Institut du Thorax, INSERM, CNRS, Nantes University Hospital, France.
“We were also interested in positive outcomes, such as returning home or to a nursing home, transfer to another hospital, or follow-up care,” Wargny noted.
The study found that after 28 days, 577 patients (20.6 percent) had died and 1,404 (50.2 percent) had been discharged. The median length of hospital stay was 9 days.
Wargny added, “We also found that 12.2 percent of patients were still in the hospital and 16.9% were referred.”
The researchers also noted that this could vary depending on the prevalence of the virus in the current situation.
He added that the researchers “were able to identify the main prognostic risk factors, both negative and positive.”
Among the risk factors that led to poorer outcomes, age was the most important. This was followed by a history of microvascular complications, in particular kidney and eye damage, shortness of breath on admission, and markers of inflammation (white blood cell count, increased C-reactive protein and increased aspartate transaminase).
Among the positive risk factors, the researchers identified routine metformin treatment and a history of Covid-19 symptoms prior to hospitalization.